ASAFO & CO. advised SPE AIF I, a private equity fund managed by SPE Capital Partners, on its acquisition of Saham Pharma, the leading antibiotics manufacturer and major hospital provider in Morocco.
On April 9, SPE AIF I, a private equity fund managed by SPE Capital Partners, announced its acquisition of Saham Pharma, the leading antibiotics manufacturer and major hospital provider in Morocco. The Asafo & Co. team advising SPE AIF I was led by Benoit de Monval (partner) and Cyril Kalfat (associate), based in the Casablanca office. The transaction was completed alongside the senior management team of Saham Pharma with Proparco as co-investor, and is the fourth transaction executed through SPE AIF I, an Africa-focused private equity fund.